3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
5
Phase 2
3
Phase 1/2
3
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Recurrence
1
Neoplasms, Plasma Cell
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Interventions
Doxorubicin
26
Bleomycin
24
Vinblastine
21
Dacarbazine
20
Vincristine
18
Cyclophosphamide
16
Radiotherapy
14
Etoposide
13
Prednisone
12
Filgrastim
11
ABVD protocol
10
Procarbazine
8
Peripheral Blood Stem Cell Transplantation
7
Granulocyte Colony-Stimulating Factor
7
Brentuximab Vedotin
6
pegfilgrastim
5
Methotrexate
5
Dexamethasone
5
Cytarabine
5
Cyclosporine
5
Prednisolone
4
Mycophenolic Acid
4
Mechlorethamine
4
Cyclosporins
4
Cisplatin
4
Whole-Body Irradiation
3
Vinorelbine
3
Radiation
3
Ifosfamide
3
Epoetin Alfa
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hodgkin Disease
×
Panobinostat
×
Clear all
NCT01034163
2016-07-07
PATH
Novartis
Phase 3
Completed
41 enrolled
7 charts